Home Medical Devices Small Animal Imaging Market Size, Trends & Growth | By 2033

Small Animal Imaging Market Size, Share & Trends Analysis Report By Technology (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography (SPECT), Optical Imaging, Photoacoustic Imaging, Others), By Applications (Drug Discovery and Disease Modeling, Preclinical Drug Development, Clinical Trials, Others), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organization) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRMD56819DR
Last Updated : Jan 27, 2025
Author : Debashree Bora
Starting From
USD 2300
Buy Now

Small Animal Imaging Market Size

The global small animal imaging market size was valued at USD 1.22 billion in 2024 and is projected to grow from USD 1.33 billion in 2025 to USD 2.22 billion by 2033, exhibiting a CAGR of 6.57% during the forecast period (2025 – 2033).

Small animal imaging refers to the non-invasive visualization and analysis of biological processes in small laboratory animals, such as mice and rats, which are widely utilized in preclinical research. This technique employs advanced imaging modalities, including positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, and ultrasound, to study disease progression, monitor treatment efficacy, and support drug development.

By providing high-resolution anatomical, functional, and molecular insights, small animal imaging enables researchers to investigate complex biological systems in vivo, significantly reducing the need for invasive procedures. It serves as a critical tool in translational research, bridging laboratory discoveries and clinical applications while accelerating drug discovery and development processes.

The global market is experiencing rapid growth, driven by advancements in imaging technologies such as high-field systems and multimodal imaging. These innovations enable more detailed studies on disease progression, drug efficacy, and tumor metabolism. High-resolution imaging techniques like MRI and PET/CT are fostering breakthroughs in drug discovery, oncology, neurology, and cardiovascular research.

The below graph shows the analysis of the use of small animals in preclinical research in 2024.

Source: Straits Research, Journal of Pharmacology and Pharmacotherapeutics

According to the data, mice accounted for 75.98% of animals used in preclinical research studies, followed by rats at 22.12%. Moreover, emerging markets in the Asia-Pacific region offer untapped growth potential, fueled by increasing investments in the biotechnology and pharmaceutical sectors. These developments present significant opportunities for the small animal imaging market, particularly in areas such as drug development, disease modeling, and preclinical testing across various therapeutic fields.

Small Animal Imaging Market Trends

Adoption of high-field systems imaging

The growing adoption of high-field imaging systems is a key trend shaping the global market. These advanced systems deliver exceptional resolution, enabling detailed research in neuroscience, oncology, and drug development. High-field imaging facilitates precise disease modeling and therapeutic evaluation, supported by innovations in hybrid technologies and AI-driven enhancements.

  • In March 2024, Siemens Healthineers launched the MAGNETOM Terra.X, a state-of-the-art 7T MRI scanner designed for ultra-high-resolution imaging in small animal research. This system is particularly suited for neuroscience, oncology, and cardiovascular studies, offering unparalleled visualization capabilities and AI-driven tools for longitudinal, non-invasive research.

The increasing adoption of such high-field systems, powered by ongoing technological advancements, is driving innovation and expanding the scope of preclinical research.

Integration of multimodal imaging systems

Another transformative trend in the global market is the integration of multimodal imaging systems. Combining techniques such as positron emission tomography (PET)/computed tomography (CT), PET/magnetic resonance imaging (MRI), and optical imaging with ultrasound or MRI provides comprehensive insights into disease mechanisms, tumor metabolism, and drug efficacy.

  • For instance, in October 2024, a study published in Laser & Photonics Reviews introduced a continuous rotational scanning photoacoustic computed tomography (PACT) system. This advanced system combines the advantages of optical and ultrasound imaging, offering rapid imaging capabilities for living organisms.

These advancements underscore the pivotal role of high-field and multimodal imaging systems in preclinical studies. By facilitating breakthroughs across neuroscience, oncology, and other therapeutic areas, they not only boost market growth but also redefine the possibilities of small animal imaging in translational research.


Small Animal Imaging Market Growth Factors

Increasing focus on personalized oncology treatment

The rising emphasis on personalized oncology treatment is significantly driving advancements in imaging technologies and targeted therapies. By tailoring treatments to individual patient profiles, these innovations enhance efficacy and reduce side effects, making small animal models indispensable for preclinical research and therapeutic evaluations.

  • For example, in April 2024, GE HealthCare unveiled the Revolution RT at the ESTRO 2024 Congress. This cutting-edge radiation therapy CT solution integrates an AI-powered Intelligent Radiation Therapy (iRT)platform with the Spectronic MRI Planner, delivering exceptional imaging precision and streamlining oncology workflows. As part of GE's MIM Software portfolio, the solution offers advanced tools for personalized cancer care.

The growing adoption of advanced imaging technologies, coupled with personalized oncology treatment strategies, is transforming both clinical and preclinical research landscapes. These innovations are not only enhancing cancer treatment outcomes but are also fueling the expansion of the global market.

Market Restraining Factors

Limited resolution for deep tissue imaging in small animals

A significant challenge in the global market is the limited resolution for deep tissue imaging. As imaging depth increases, high-resolution image quality deteriorates due to factors such as light scattering, tissue absorption, and inherent limitations of existing imaging modalities. These challenges hinder clear visualization of deeper anatomical structures, making it difficult to accurately assess tumor progression or conduct detailed diagnostic and therapeutic evaluations. Such constraints impact the precision of research outcomes and limit advancements in preclinical studies.

Small Animal Imaging Market Opportunities

Collaborative research and clinical research organization (CRO) partnerships

Collaborative efforts between pharmaceutical companies and clinical research organizations (CROs) present a promising growth opportunity for the global small animal imaging market. These partnerships leverage specialized expertise and resources, expediting drug development and preclinical research.

For instance,

  • In August 2024, Silo Pharma, Inc., a biopharmaceutical company, partnered with WuXi AppTec Limited, a leading CRO, to conduct a preclinical small animal study of SPU-16, a CNS-targeting peptide for multiple sclerosis (MS). This collaboration highlights the growing role of CROs in facilitating preclinical studies and advancing drug discovery.
  • Similarly, in August 2024, Skanray, a MedTech company, partnered with Tata Elxsi to develop advanced surgical imaging technology. This collaboration aims to revolutionize diagnosis and treatment by delivering accurate, predictable, and consistent imaging solutions.

Such partnerships not only accelerate research timelines but also drive innovation, positioning the global market for significant growth in preclinical applications.

Study Period 2021-2033 CAGR 6.57%
Historical Period 2021-2023 Forecast Period 2025-2033
Base Year 2024 Base Year Market Size USD 1.22 billion
Forecast Year 2033 Forecast Year Market Size USD 2.22 billion
Largest Market North America Fastest Growing Market Asia-Pacific
Talk to us
If you have a specific query, feel free to ask our experts.

Regional Insights

North America: Dominant region with 40.37% market share

North America maintains a dominant position in the global market, driven by the presence of advanced research facilities, a robust biotechnology and pharmaceutical industry, and significant investments in healthcare innovation. The region hosts numerous academic institutions, private research organizations, and companies actively engaged in drug discovery, disease modeling, and preclinical studies, fueling the demand for cutting-edge imaging technologies. Moreover, strong regulatory support and high adoption rates of innovative imaging solutions bolster North America’s leadership in the market.

Asia-Pacific: Fastest growing region with the highest CAGR

Asia-Pacific is projected to witness the fastest CAGR, attributed to increasing investments in biotechnology and pharmaceutical industries. A growing emphasis on preclinical research, coupled with expanding clinical trials and drug development activities in countries like China, Japan, and India, is driving demand for advanced imaging technologies. This rapid growth is further supported by government initiatives and collaborations aimed at enhancing healthcare infrastructure and fostering innovation in small animal imaging.

Country Insights

  • U.S.- The U.S. is a leader in the small animal imaging industry due to its advanced biotechnology infrastructure, high levels of investment in research and developments, and merger and acquisition of leading small animal imaging companies. For instance, in November 2024, Radon Medical Imaging acquired Alpha Imaging, a major distributor and servicer of medical imaging equipment in the U.S., strengthening its service capabilities and expanding its market reach.
  • Germany- Germany stands as one of the largest markets for small animal imaging in Europe, driven by strong collaborations between biotechnology companies and healthcare institutions for extensive research studies. In October 2024, GE HealthCare partnered with University Medicine Essen to establish a theranostics center of excellence. Equipped with cutting-edge technologies, the center aims to advance personalized cancer care research and clinical practice, further propelling the growth of theranostic and personalized medicine in oncology.
  • Singapore- The Singapore market for small animal imaging is driven by collaboration between contract research organizations and research institutions for preclinical small animal studies. In May 2024, Ora, Inc., a leading CRO, partnered with the Singapore Eye Research Institute (SERI) to advance ophthalmic research and preclinical studies. SERI, a leader in non-clinical ophthalmic animal studies, specializes in translatable ocular models in small animal species to evaluate therapies for ocular diseases.
  • India– India is experiencing rapid growth in the market, fueled by government funding and the establishment of new research facilities. In July 2024, India inaugurated Asia's first Pre-clinical Network Facility under the Coalition of Epidemic Preparedness Innovations (CEPI) at the Regional Centre of Biotechnology, Faridabad. This facility advances preclinical research, supporting small animal imaging by enhancing disease modeling, drug testing, and vaccine development.
  • China- China’s market for small animal imaging is expanding quickly, driven by significant investments in biomedical research and advancements in imaging technologies. The growing focus on drug discovery and development, combined with government support for research initiatives, continues to foster a strong environment for global market growth. This combination of private and public sector investments positions China as a key player in the global market.
  • UK- The UK market for small animal imaging is progressing steadily, supported by a strong emphasis on preclinical research, government funding for biomedical research, and advancements in imaging technologies. The country’s leading academic and research institutions play a pivotal role in driving market growth, with many institutions conducting cutting-edge research in disease modeling, drug discovery, and imaging technology development.
  • Japan- Japan is seeing significant growth in its market, driven by advancements in imaging technologies and government support for biomedical research. The country’s increasing focus on preclinical research, particularly in drug discovery and disease modeling, further fuels demand for small animal imaging. Japan’s well-established research infrastructure and growing biotech sector continue to propel the market’s expansion.
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Segmentation Analysis

The global small animal imaging market is segmented into technology, application, and end-user.

By Technology

The optical imaging segment dominates the market, generating the highest revenue. Its non-invasive nature, high sensitivity, and ability to provide detailed, real-time imaging at a low cost make it indispensable for disease modeling, drug discovery, and therapeutic evaluation. For instance, in October 2024, researchers from Hebrew University introduced image-guided computational holographic wavefront shaping, as reported by the European Research Council. This innovation revolutionizes optical imaging by enabling fast, non-invasive visualization through scattering media, addressing complex imaging challenges effectively.

By Application

The drug discovery and disease modeling segment held the largest market revenue in the global market. Small animals are extensively used to evaluate drug efficacy and study disease mechanisms, particularly in oncology, neurology, and cardiovascular research. These models provide critical in vivo insights into therapeutic effectiveness and safety, accelerating preclinical research. By offering reliable data on drug interactions and disease progression, this segment plays a crucial role in advancing novel treatments and improving the efficiency of drug development pipelines globally.

By End-User

Pharmaceutical and biotechnology companies dominate the market, holding the highest market share. These organizations rely on advanced imaging technologies for drug discovery, preclinical testing, and therapeutic evaluations. By using small animal models, they assess drug efficacy, toxicity, and safety before proceeding to human trials. This reliance on small animal imaging enables companies to streamline the drug development process, ensuring more precise and effective treatments while reducing research and development timelines. 

Market Size By Technology

Market Size By Technology
Computed Tomography (CT) Magnetic Resonance Imaging (MRI) Single Photon Emission Computed Tomography (SPECT) Optical Imaging Photoacoustic Imaging Others

List of key players in Small Animal Imaging Market

  1. Laboratory Corporation of America
  2. Lonza
  3. WuXi AppTec, Inc.
  4. Eurofins Scientific SE
  5. Intertek Group plc
  6. Medpace Holdings, Inc.
  7. Charles River Laboratories International, Inc.
  8. SGA SA
  9. ICON plc
  10. CROWN bioscience
  11. Miltenyi Biotec GmbH
  12. FUJIFILM Holdings Corporation
  13. MILabs B.V.
  14. LI-COR Biosciences
  15. Mediso Ltd
Small Animal Imaging Market Share of Key Players

Company Market Share

Key players in the small animal imaging industry are actively focusing on adopting a range of strategic business initiatives to strengthen their position in the market. These strategies include strategic collaborations, where companies partner with academic institutions, pharmaceutical firms, and contract research organizations (CROs) to accelerate innovation and expand their research capabilities. Product approvals from regulatory bodies, such as the FDA and CE Mark certifications, are crucial for ensuring market entry and growth in new regions.

MILabs B.V.: An emerging player in the global small animal imaging market

MILabs B.V. is a leading provider of innovative imaging solutions specializing in small animal imaging systems. The company develops advanced technologies for molecular imaging, offering tools for preclinical research in oncology, neurology, and drug development. MILabs focuses on providing high-resolution imaging systems that combine PET, SPECT, CT, and MRI for comprehensive, non-invasive studies.

Recent developments by MILabs B.V.:

  • In March 2024, MILabs partnered with Mid-Atlantic Imaging Services to offer installation and support for its imaging systems in the US and Canada. This agreement enhances access to MILabs' small animal imaging technologies, supporting research in drug discovery and disease modeling.

Analyst Opinion

As per our analysts, the global market is poised for remarkable growth, driven by continuous advancements in high-field imaging systems and the development of innovative multi-modal imaging technologies. These cutting-edge solutions enable researchers to gain comprehensive insights into disease progression, tumor metabolism, and drug efficacy in small animals, making them indispensable tools in preclinical research.

Despite its promising outlook, the market faces certain challenges, including the limited resolution of deep tissue imaging, which hinders the visualization of deeper anatomical structures. Moreover, the high costs of advanced imaging systems and the requirement for specialized expertise in operating these technologies pose barriers to adoption, particularly in resource-constrained settings.

However, the continuous evolution of imaging modalities, coupled with growing cross-industry collaborations and a rising focus on personalized medicine, is expected to drive sustained market expansion. With its broadening applications in oncology, neurology, and cardiovascular research, the small animal imaging industry is set to remain a cornerstone of preclinical research advancements.

Recent Developments

  • August 2024 – A research team from IOCB Prague, in collaboration with the University of Tübingen and the Faculty of Science, Charles University, developed a groundbreaking contrast agent for both MRI and PET. This innovation overcomes previous limitations in combining these imaging techniques, offering enhanced diagnostic potential, particularly for kidney diseases and tumors.

Small Animal Imaging Market Segmentations

By Technology (2021-2033)

  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Single Photon Emission Computed Tomography (SPECT)
  • Optical Imaging
  • Photoacoustic Imaging
  • Others

By Applications (2021-2033)

  • Drug Discovery and Disease Modeling
  • Preclinical Drug Development
  • Clinical Trials
  • Others

By End-User (2021-2033)

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organization

Frequently Asked Questions (FAQs)

How much is the organoids market worth?
Straits research predicts that the global small animal imaging market size was valued at USD 1.22 billion in 2024 and is projected to grow from USD 1.33 billion in 2025 to USD 2.22 billion by 2033
The global market growth rate growing at a 6.57% from 2025 to 2033.
Increasing focus on personalized oncology treatment, is a key growth factor driving advancements in global industry.
North America holds the largest market share in organoids industry
Currently, the intestinal drug discovery segment dominates the market


We are featured on :